Articles tagged with: Carfilzomib

News»

[ by | Dec 8, 2013 5:16 pm | 4 Comments ]
ASH 2013 Multiple Myeloma Update - Day One

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.

During the session, research results were made available for review by meeting attendees in …

Read the full story »

News»

[ by and | Sep 20, 2013 4:57 pm | One Comment ]
Kyprolis-Revlimid-Dexamethasone Combination Continues To Show Promise For Relapsed Myeloma

Results from a recent Phase 2 trial indicate that the combination of Kyprolis, Revlimid, and dexamethasone is effective in relapsed multi­ple myeloma patients.

Specifically, the results show that 77 percent of patients responded to the treat­ment. The investigators point out the responses seen in the trial were rapid (median time to response was one month) and robust (medi­an duration of response was 22 months).

According to the investigators, the results are particularly encouraging because one-quarter of the patients were refractory (resistant) to Velcade (bortezomib) and almost half were …

Read the full story »

News»

[ by and | Sep 4, 2013 9:21 pm | 2 Comments ]
Kyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?

A new retrospective study provides insight into the benefit the new mye­lo­ma drugs Kyprolis and Pomalyst may provide to patients who are re­sis­tant to, or cannot tolerate, both Velcade and Revlimid.

The study's results highlight how challenging it can be to find an effective treat­ment for patients who are “dual refractory” (resistant to both Velcade and Rev­li­mid).

Patients in the study who received either Kyprolis (carfilzomib) or Poma­lyst (poma­lido­mide, Imnovid) after becoming dual refractory had longer overall survival than those who were not treated with the new …

Read the full story »

News»

[ by | Aug 26, 2013 12:41 pm | 3 Comments ]
Amgen To Acquire Onyx, Maker Of Kyprolis; What Does It Mean For The Myeloma Community?

Onyx Pharmaceuticals, the South San Francisco, California-based com­pany that developed and now mar­kets Kyprolis (carfilzomib), announced yesterday eve­ning that it is being acquired by Amgen.

Amgen (NASDAQ:AMGN), which is based outside of Los Angeles, is the world’s largest biotech company.

Within the multiple myeloma community, Amgen is known most for its anemia medications – Aranesp (darbe­poetin alfa) and Epogen (epoetin alfa, also mar­keted as Procrit and Eprex) – as well as its drugs that in­crease the body’s production of white blood cells – Neupogen (filgra­stim) and

Read the full story »

News»

[ by | Updated: Jun 19, 2013 11:10 pm | Comments Off ]
The European Hematology Association’s Annual Congress Starts Today: A Look At The Key Myeloma-Related Presentations (EHA 2013)

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year.  The first education and poster sessions of the meet­ing will take place tomorrow, Friday, June 14.  Additional sessions of vari­ous kinds are scheduled for both days of the weekend, until the meet­ing ends early Sunday afternoon (European time).

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related dis­eases, in­clud­ing multiple myeloma.

The EHA …

Read the full story »